KR20230087572A - 혈액 장애를 치료하기 위한 조성물 및 방법 - Google Patents

혈액 장애를 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20230087572A
KR20230087572A KR1020237016264A KR20237016264A KR20230087572A KR 20230087572 A KR20230087572 A KR 20230087572A KR 1020237016264 A KR1020237016264 A KR 1020237016264A KR 20237016264 A KR20237016264 A KR 20237016264A KR 20230087572 A KR20230087572 A KR 20230087572A
Authority
KR
South Korea
Prior art keywords
antibody
seq
amino acid
acid sequence
thrombocytopenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237016264A
Other languages
English (en)
Korean (ko)
Inventor
테드 예드녹
세투 산카라나라야난
Original Assignee
애넥슨, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애넥슨, 인코포레이티드 filed Critical 애넥슨, 인코포레이티드
Publication of KR20230087572A publication Critical patent/KR20230087572A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237016264A 2020-10-16 2021-10-15 혈액 장애를 치료하기 위한 조성물 및 방법 Pending KR20230087572A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063093029P 2020-10-16 2020-10-16
US63/093,029 2020-10-16
PCT/US2021/055216 WO2022081997A1 (en) 2020-10-16 2021-10-15 Compositions and methods for treating blood disorders

Publications (1)

Publication Number Publication Date
KR20230087572A true KR20230087572A (ko) 2023-06-16

Family

ID=81208704

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237016264A Pending KR20230087572A (ko) 2020-10-16 2021-10-15 혈액 장애를 치료하기 위한 조성물 및 방법

Country Status (8)

Country Link
US (1) US20230391858A1 (https=)
EP (1) EP4228696A4 (https=)
JP (1) JP2023545501A (https=)
KR (1) KR20230087572A (https=)
AU (1) AU2021361067A1 (https=)
CA (1) CA3195798A1 (https=)
MX (1) MX2023004429A (https=)
WO (1) WO2022081997A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
WO2023114763A1 (en) * 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) * 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
HUE070383T2 (hu) * 2014-11-05 2025-06-28 Annexon Inc Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik
WO2017091719A1 (en) * 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
WO2021076991A1 (en) * 2019-10-17 2021-04-22 Annexon, Inc. Compositions and methods for treating blood disorders

Also Published As

Publication number Publication date
AU2021361067A1 (en) 2023-06-01
EP4228696A1 (en) 2023-08-23
US20230391858A1 (en) 2023-12-07
WO2022081997A1 (en) 2022-04-21
EP4228696A4 (en) 2025-03-26
AU2021361067A9 (en) 2024-07-11
CA3195798A1 (en) 2022-04-21
JP2023545501A (ja) 2023-10-30
MX2023004429A (es) 2023-07-11

Similar Documents

Publication Publication Date Title
JP7275223B2 (ja) ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
JP7809056B2 (ja) 血液障害を処置するための組成物及び方法
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
JP2020002176A (ja) 補体のインヒビターによる発作性夜間血色素尿症患者の処置
US11623956B2 (en) Anti-human CD19 antibodies
KR20190005944A (ko) 척수성 근위축 치료용 조성물 및 방법
CA3030872A1 (en) Compositions and methods for treating frontotemporal dementia
CN116782940A (zh) 用于治疗眼部疾病的组合物和方法
KR20230087572A (ko) 혈액 장애를 치료하기 위한 조성물 및 방법
JP2024539141A (ja) 筋ジストロフィーを治療するための組成物及び方法
US20240034775A1 (en) Compositions and methods for treating epilepsy
EP3787682B1 (en) Use of epithelial membrane protein 2 (emp2) targeting agents in treating lung disorders
HK40077291A (en) Compositions and methods for treating blood disorders
KR20240126863A (ko) 헌팅턴병 치료용 조성물 및 방법
CN119677537A (zh) 用于治疗狼疮性肾炎的组合物和方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230512

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241015

Comment text: Request for Examination of Application